Abstract\r\nZidovudine the first anti-HIV compound approved for clinical use is widely used for treatment of AIDS either alone or in combination with other antiviral agents. Zidovudine is a di-deoxynucleoside compound in which 3- hydroxy groups on the sugar moiety can be replaced by group and this modification prevents the formanation of phosphodiester linkages which are needed for the completion of nucleic acid chain. Zidovudine appears most promising because it crosses the blood brain barrier and be taken orally. The main limitation to therapeutic effectiveness of zidovudine is its dose-dependent hematological toxicity, low therapeutic index, short biological half-life of 0.8-1.5 hours, and poor bioavailability 65% after its administration. So in order to improve the bioavailability, efficacy and to minimize the side effect associates with other drug delivery system, we have prepared gas powered system tablet of zidovudine using natural polymer mangifera indica. All the prepared tablets are able to float up to 24 hr, smooth, uniform in weight, thickness. The polymer used mangifera indica shows an increase in vitro residence time and is mainly due to swelling property of mangifera indica. Drug content uniformity study shoes uniform distribution of the drug throughout the formulation in the range 96.98 to 99.96%. The invitro drug release study shows that more than 95% of the drug was released at the end of 24 hr. the release profile of all the formulation is subjected to kinetic equations.
Loading....